Evidence map›Paper›PMID 42712968›Full record

ArticleFrontiers in immunology2026

Low-dose allergen targeting to cDC2 induces long-term protection associated with induction of regulatory-like IL-10

Arpa Aintablian, Laura Cyran, Moutaz Helal, Christian H K Lehmann, Fabian Imdahl, Tom Gräfenhan, Angela Riedel, Diana Dudziak, Andreas Kerstan, Manfred B Lutz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Arpa Aintablian *Institute for Virology and Immunobiology, University of Würzburg, Würzburg, Germany.
Laura Cyran *Institute for Virology and Immunobiology, University of Würzburg, Würzburg, Germany.
Moutaz HelalMildred Scheel Early Career Centre (MSNZ) for Cancer Research, Würzburg, University Hospital Würzburg, and University of Würzburg, Würzburg, Germany.
Christian H K LehmannCELLIKON, Department of Dermatology, University Hospital Erlangen, Erlangen, Germany.
Fabian ImdahlSingle-Cell Center Würzburg, Helmholtz Institute for RNA-based Infection Research, Würzburg, Germany.
Tom GräfenhanCore Unit Systems Medicine, University of Würzburg, Würzburg, Germany.
Angela RiedelMildred Scheel Early Career Centre (MSNZ) for Cancer Research, Würzburg, University Hospital Würzburg, and University of Würzburg, Würzburg, Germany.
Diana DudziakLaboratory of Dendritic Cell Biology, Department of Dermatology, University Hospital Erlangen, Erlangen, Germany.
Andreas KerstanDepartment of Dermatology, Venerology and Allergology, University Hospital Würzburg, Würzburg, Germany.
Manfred B LutzInstitute for Virology and Immunobiology, University of Würzburg, Würzburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prevalence of allergic diseases is rising worldwide. Desensitizing immunotherapy is currently the only available treatment, but it is often ineffective for certain allergies, underscoring the need for new treatments. This study tested in an Ovalbumin (OVA)-mediated allergy mouse model whether direct allergen targeting to DC subsets can induce desensitization. A Standard desensitization protocol was compared with an antibody-OVA fusion protein targeting the conventional cDC1 or cDC2 subsets via their respective receptors CD205 (CD205-Fp) or DCIR2 (DCIR2-Fp). Allergen targeting to cDC2 provided long-lasting protection for up to 56 days after desensitization with only nanogram doses of allergen, whereas the Standard therapy protected for only 20 days, requiring microgram doses and repeated injections with Alum adjuvant. CD205-Fp showed no protective effect. Blocking IL-10 either before administering DCIR2-Fp or before allergen challenge completely abolished protection. Standard therapy had moderate effects on CD4

Indexed as

AllergensCD8-Positive T-LymphocytesDendritic CellsDesensitization, ImmunologicHypersensitivityT-Lymphocytes, RegulatoryAnimalsDisease Models, AnimalFemaleForkhead Transcription FactorsInterleukin-10MiceMice, Inbred BALB COvalbuminAllergensForkhead Transcription FactorsFoxp3 protein, mouseIL10 protein, mouseInterleukin-10OvalbuminallergyCD8 regulatory T cellsdendritic cellstargetingtherapy

Identifiers

PMID42712968
PMCPMC13551728

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.